Sydnexis Incis A Clinical Stage Biopharmaceutical Company Based In Del Marcaliforniafounded In 2014The Company Is Dedicated To Developing Treatments For Myopiaparticularly In Childrenwith The Aim Of Slowing Its Progression And Reducing Related Eye Health Issues The Company S Lead Candidatesyd 101Is A Patented Eye Drop Formulation Currently Undergoing A Phase 3 Clinical Trialthis Innovative Formulation Of Low Dose Atropine Is Designed To Address The Growing Concern Of Myopia In Pediatric Patientssydnexis Is Focused On Pediatric Ophthalmologytargeting Healthcare Providers And Families Seeking Effective Treatments For Children With Progressive Myopia Sydnexis Has Successfully Raised Significant Funding To Support Its Clinical Trials And Product Developmenttotaling $51 5 Millionthe Company Has Also Filed 33 Patents Related To Its Research And Development Effortsincluding A Notable Patent For D2O Stabilized Pharmaceutical Formulations
